An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and...
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic...
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), today announced that an abstract providing updated data from the...
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC's Phase 1 China study indicates differentiation from PADCEV ...
Corbus Reports Fourth Quarter and Year-End 2023 Financial Results
Corbus to Participate in the BMO Capital Markets Inaugural Obesity Summit
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a precision oncology company with a diversified portfolio, today...